Antibiotic Use in Hospital Urinary Tract Infections After FDA Regulation.
antibiotics
government regulation
urinary tract infection
Journal
Journal of general internal medicine
ISSN: 1525-1497
Titre abrégé: J Gen Intern Med
Pays: United States
ID NLM: 8605834
Informations de publication
Date de publication:
26 Dec 2023
26 Dec 2023
Historique:
received:
18
07
2023
accepted:
01
12
2023
medline:
27
12
2023
pubmed:
27
12
2023
entrez:
26
12
2023
Statut:
aheadofprint
Résumé
The FDA issued a "black box" warning regarding risks of fluoroquinolones in 2008 with updates in 2011, 2013, and 2016. To examine antimicrobial use in hospital-treated UTIs from 2000 to 2020. Cross-sectional study with interrupted time series analysis. Patient encounters with a diagnosis of UTI from January 2000 to March 2020, excluding diagnoses of renal abscess, chronic cystitis, and infection of the gastrointestinal tract, lungs, or prostate. Monthly use of fluoroquinolone and non-fluoroquinolone antibiotics were assessed. Fluoroquinolone resistance was assessed in available cultures. Interrupted time series analysis examined level and trend changes of antimicrobial use with each FDA label change. A total of 9,950,790 patient encounters were included. From July 2008 to March 2020, fluoroquinolone use declined from 61.7% to 11.7%, with similar negative trends observed in inpatients and outpatients, age ≥ 60 and < 60 years, males and females, patients with and without pyelonephritis, and across physician specialties. Ceftriaxone use increased from 26.4% encounters in July 2008 to 63.6% of encounters in March 2020. Among encounters with available culture data, fluoroquinolone resistance declined by 28.9% from 2009 to 2020. On interrupted time series analysis, the July 2008 FDA warning was associated with a trend change (-0.32%, < 0.001) and level change (-5.02%, p < 0.001) in monthly fluoroquinolone use. During this era of "black box" warnings, there was a decline in fluoroquinolone use for hospital-treated UTI with a concomitant decline in fluoroquinolone resistance and rise in ceftriaxone use. Efforts to restrict use of a medication class may lead to compensatory increases in use of a single alternative agent with changes in antimicrobial resistance profiles.
Sections du résumé
BACKGROUND
BACKGROUND
The FDA issued a "black box" warning regarding risks of fluoroquinolones in 2008 with updates in 2011, 2013, and 2016.
OBJECTIVE
OBJECTIVE
To examine antimicrobial use in hospital-treated UTIs from 2000 to 2020.
DESIGN
METHODS
Cross-sectional study with interrupted time series analysis.
PARTICIPANTS
METHODS
Patient encounters with a diagnosis of UTI from January 2000 to March 2020, excluding diagnoses of renal abscess, chronic cystitis, and infection of the gastrointestinal tract, lungs, or prostate.
MAIN MEASURES
METHODS
Monthly use of fluoroquinolone and non-fluoroquinolone antibiotics were assessed. Fluoroquinolone resistance was assessed in available cultures. Interrupted time series analysis examined level and trend changes of antimicrobial use with each FDA label change.
KEY RESULTS
RESULTS
A total of 9,950,790 patient encounters were included. From July 2008 to March 2020, fluoroquinolone use declined from 61.7% to 11.7%, with similar negative trends observed in inpatients and outpatients, age ≥ 60 and < 60 years, males and females, patients with and without pyelonephritis, and across physician specialties. Ceftriaxone use increased from 26.4% encounters in July 2008 to 63.6% of encounters in March 2020. Among encounters with available culture data, fluoroquinolone resistance declined by 28.9% from 2009 to 2020. On interrupted time series analysis, the July 2008 FDA warning was associated with a trend change (-0.32%, < 0.001) and level change (-5.02%, p < 0.001) in monthly fluoroquinolone use.
CONCLUSIONS
CONCLUSIONS
During this era of "black box" warnings, there was a decline in fluoroquinolone use for hospital-treated UTI with a concomitant decline in fluoroquinolone resistance and rise in ceftriaxone use. Efforts to restrict use of a medication class may lead to compensatory increases in use of a single alternative agent with changes in antimicrobial resistance profiles.
Identifiants
pubmed: 38148474
doi: 10.1007/s11606-023-08559-9
pii: 10.1007/s11606-023-08559-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Society of General Internal Medicine.
Références
Tanne JH. FDA adds "black box" warning label to fluoroquinolone antibiotics. BMJ. 2008;337(7662):a816. Published 2008 Jul 15. https://doi.org/10.1136/bmj.a816.
FDA Updates Warnings for Fluoroquinolone Antibiotics. U.S. Food and Drug Administration, FDA, https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics . Accessed 29 Dec 2021.
Tran PT, Antonelli PJ, Hincapie-Castillo JM, Winterstein AG. Association of US Food and Drug Administration removal of indications for use of oral quinolones with prescribing trends. JAMA Intern Med. 2021;181(6):808-816. https://doi.org/10.1001/jamainternmed.2021.1154.
Sankar A, Swanson KM, Zhou J, et al. Association of fluoroquinolone prescribing rates with black box warnings from the US Food and Drug Administration. JAMA Netw Open. 2021;4(12):e2136662. https://doi.org/10.1001/jamanetworkopen.2021.36662.
Jeong IG, Khandwala YS, Kim JH, et al. Association of robotic-assisted vs laparoscopic radical nephrectomy with perioperative outcomes and health care costs, 2003 to 2015. JAMA. 2017;318(16):1561-1568.
Xiong S, Liu X, Deng W, Zhou Z, Li Y, Tu Y, Chen L, Wang G, Fu B. Pharmacological interventions for bacterial prostatitis. Front Pharmacol. 2020;11:504. https://doi.org/10.3389/fphar.2020.00504 .
Widen A, Waldman B. Petition for a Black Box Warning on Fluoroquinolone Antibiotics. Public Citizen, 29 Aug. 2006, https://www.citizen.org/article/petition-for-a-black-box-warning-on-fluoroquinolone-antibiotics/ . Accessed 3 Feb 2022.
McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis. 2007;45(9):1141-1151. https://doi.org/10.1086/522187.
Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254-1260. https://doi.org/10.1086/496986.
Park SH. Third-generation cephalosporin resistance in gram-negative bacteria in the community: a growing public health concern. Korean J Intern Med. 2014;29(1):27-30. https://doi.org/10.3904/kjim.2014.29.1.27.
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. https://doi.org/10.1016/S0140-6736(21)02724-0.
Rubino A, Sanon M, Ganz ML, et al. Association of the US Food and Drug Administration antipsychotic drug boxed warning with medication use and health outcomes in elderly patients with dementia. JAMA Netw Open. 2020;3(4):e203630. Published 2020 Apr 1. https://doi.org/10.1001/jamanetworkopen.2020.3630.
Yarrington ME, Anderson DJ, Dodds Ashley E, et al. Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals. Infect Control Hosp Epidemiol. 2019;40(11):1297-1300. https://doi.org/10.1017/ice.2019.247.
Ebell MH. Treating adult women with suspected UTI. Am Fam Physician. 2006;73(2):293-296.
Lee RA, Centor RM, Humphrey LL, et al. Appropriate use of short-course antibiotics in common infections: best practice advice from the American College of Physicians. Ann Intern Med. 2021;174(6):822-827. https://doi.org/10.7326/M20-7355.
Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Guideline. J Urol. 2019;202(2):282-289. https://doi.org/10.1097/JU.0000000000000296.